Antivirals, Including Antibody Products
These sections summarize the data on antiviral agents, including remdesivir, ritonavir-boosted nirmatrelvir, and anti-SARS-CoV-2 monoclonal antibodies.
Read the Panel’s recommendations on the use of antiviral agents for the treatment of COVID-19 and for SARS-CoV-2 PrEP.
Remdesivir is a nucleotide analogue prodrug that is approved to treat COVID-19 in certain patients.
Read about using ritonavir-boosted nirmatrelvir in patients with COVID-19.
Read about using molnupiravir in patients with COVID-19.
Learn about monoclonal antibodies that target the SARS-CoV-2 spike protein.
Plasma from donors who have recovered from COVID-19 may contain SARS-CoV-2 antibodies.
Interferons are a group of antiviral cytokines that are being evaluated to treat COVID-19.
Review the characteristics of the antiviral agents that are under evaluation for the treatment of COVID-19 or for SARS-CoV-2 PrEP.